Bharat Biotech’s Covaxin Not Upto Manufacturing Standards, Says Brazil

Rio de Janeiro: Brazil’s health regulator Anvisa has said that Covaxin did not meet its manufacturing standards.

The Brazilian government had signed a contract in February to buy 20 million doses of the COVID-19 vaccine, which has been developed by Indian company Bharat Biotech.

The Brazilian government signed a contract last month to buy 20 million doses of Covaxin, Reuters reported. Bharat Biotech applied for emergency use of the vaccine in Brazil on March 8.

Following the Brazilian regulator’s announcement, Bharat Biotech and its Brazilian partner Precisa Medicamentos stated that they will appeal the decision and present evidence that the vaccine complies with all requirements.

The statement further mentioned that Covaxin has been approved for use in five countries.

Brazil, which reported a record 3,780 coronavirus deaths on Monday, currently accounts for about a quarter of COVID-19 daily deaths worldwide.